The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of immunotherapy administration for hospitalized cancer patients.
 
David W. Dougherty
Honoraria - inPractice
 
Houry Leblebjian
Consulting or Advisory Role - HERON; Stemline Therapeutics; Takeda
Travel, Accommodations, Expenses - HERON; Stemline Therapeutics; Takeda
 
Megan Duperrault
No Relationships to Disclose
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Maverick Therapeutics; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Sylvia Bartel
No Relationships to Disclose
 
Anne McDonnell
Consulting or Advisory Role - HERON; Spectra Laboratories; Takeda
 
Craig A. Bunnell
Stock and Other Ownership Interests - Amgen (I); Becton Dickinson; Bristol-Myers Squibb (I); GE Healthcare
 
Andrew J. Wagner
Honoraria - Novartis
Consulting or Advisory Role - Daiichi Sankyo; Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Chintan Pandya
No Relationships to Disclose
 
Lauren M. Hamel
No Relationships to Disclose
 
Brett Glotzbecker
No Relationships to Disclose